AD01 IRQQPRDPPTETLELEVSPDPAS-acid

  • Description

  • Application Data

Description

AD01 is a derivative of the FK506 binding protein-like (FKBPL), and exerts potent anti-angiogenic activity in vitro and in vivo to control tumour growth.

See full description

Application Data

Catalogue number crb1001113
Molecular Weight 2574.3
Sequence (one letter code) IRQQPRDPPTETLELEVSPDPAS-acid
Sequence (three letter code)

H-Ile-Arg-Gln-Gln-Pro-Arg-Asp-Pro-Pro-Thr-Glu-Thr-Leu-Glu-Leu-Glu-Val-Ser-Pro-Asp-Pro-Ala-Ser-OH

Purity >95%
Storage -20°C
References

Yakkundi et al (2013) The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PloS ONE 8(2) e55075 PMID: 23457460

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

AD01 is a derivative of the FK506 binding protein-like (FKBPL), and exerts potent anti-angiogenic activity in vitro and in vivo to control tumour growth.
Recent studies have shown that AD-01 inhibits Rac-1 activity, and up-regulates RhoA and the actin binding proteins, profilin and vinculin.
In this way, the anti-angiogenic proteins, FKBPL, and AD-01, offer a promising and alternative approach for targeting both CD44 positive tumours and vasculature networks. Recent clinical studies have shown that AD01 and other FKBPL-based peptides may offer an alternative for targeting treatment-resistant breast cancer stem cells.

AD01

Cat No.Pack SizePriceQty.
0.5mg£95.00
1mg£130.00
Bulk Quote